LongseeMed was Founded in 2015, it is an international provider of advanced core technologies, products and data related to "IVD (reagent + instrument),Functional food,Fecal microbiota transplantation,Living biological medicine,Medical care services " founded by a team of returned scholars.LongseeMed based in Guangzhou, China, the company has R&D, Data and Technical service centers in Beijing, Chongqing, Wuhan and Singapore.
Nanxin Medical established an independent third-party medical testing laboratory in 2019, and obtained the qualifications of medical institutions and ISO9001 quality management system certification that year, which can carry out clinical biochemical, cellular molecular, and immunological testing projects.
At the beginning of 2020, Nanxin Medical Inspection Laboratory obtained the qualification of clinical gene amplification laboratory and was selected as one of the 18 third-party institutions designated by Guangzhou City to conduct COVID-19 nucleic acid testing.
Nanxin Medical Inspection Laboratory has a complete infrastructure, with eight standardized negative pressure BSL-2 Plus laboratories, and world-class platform instruments: second-generation sequencing platform (two), mass spectrometry platform (two) , Liquid-phase chip platform, flow cytometry platform and multiple automation equipment, the total amount of laboratory equipment is more than 30 million yuan.
At present, Nanxin Medical Inspection Laboratory has carried out intestinal and female reproductive tract microbial testing services, pathogenic microbial metagenomic testing services, vitamin metabolism testing and human immunity assessment and other clinical major health testing services, committed to making micro-ecologies benefit mankind Health; At the same time, Nanxin Laboratories also develops multi-omics scientific research and technical services serving major universities, hospitals, and research institutes. Genomics, transcriptomics, proteomics and metabolomics are jointly combined to promote the latest biomedical industry Scientific research results.
LongseeMed was Founded in 2015, it is an international provider of advanced core technologies, products and data related to "IVD (reagent + instrument),Functional food,Fecal microbiota transplantation,Living biological medicine,Medical care services " founded by a team of returned scholars.LongseeMed based in Guangzhou, China, the company has R&D, Data and Technical service centers in Beijing, Chongqing, Wuhan and Singapore.
Nanxin Medical established an independent third-party medical testing laboratory in 2019, and obtained the qualifications of medical institutions and ISO9001 quality management system certification that year, which can carry out clinical biochemical, cellular molecular, and immunological testing projects.
At the beginning of 2020, Nanxin Medical Inspection Laboratory obtained the qualification of clinical gene amplification laboratory and was selected as one of the 18 third-party institutions designated by Guangzhou City to conduct COVID-19 nucleic acid testing.
Nanxin Medical Inspection Laboratory has a complete infrastructure, with eight standardized negative pressure BSL-2 Plus laboratories, and world-class platform instruments: second-generation sequencing platform (two), mass spectrometry platform (two) , Liquid-phase chip platform, flow cytometry platform and multiple automation equipment, the total amount of laboratory equipment is more than 30 million yuan.
At present, Nanxin Medical Inspection Laboratory has carried out intestinal and female reproductive tract microbial testing services, pathogenic microbial metagenomic testing services, vitamin metabolism testing and human immunity assessment and other clinical major health testing services, committed to making micro-ecologies benefit mankind Health; At the same time, Nanxin Laboratories also develops multi-omics scientific research and technical services serving major universities, hospitals, and research institutes. Genomics, transcriptomics, proteomics and metabolomics are jointly combined to promote the latest biomedical industry Scientific research results.